Combination therapy for osteoporosis

Details Combination therapy for osteoporosis Combination therapy for osteoporosis

2007-08-14

2007-08-14

Leith, Patricia (Department: 1627)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S091500, C435S975000, C514S428000

Reexamination Certificate

active

09736051

ABSTRACT:
Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis.

REFERENCES:
patent: 4097601 (1978-06-01), Schaaf
patent: 4621100 (1986-11-01), Lund et al.
patent: 4894373 (1990-01-01), Young
patent: 5118667 (1992-06-01), Adams et al.
patent: 5164368 (1992-11-01), Recker et al.
patent: 5216183 (1993-06-01), Sugiura et al.
patent: 5281590 (1994-01-01), Husa et al.
patent: 5409911 (1995-04-01), Tyler et al.
patent: 5441966 (1995-08-01), Dodge
patent: 5492916 (1996-02-01), Morriello et al.
patent: 5510370 (1996-04-01), Hock
patent: 5767124 (1998-06-01), Draper et al.
patent: 5773477 (1998-06-01), McLean et al.
patent: 6043026 (2000-03-01), Patchett et al.
patent: 6100301 (2000-08-01), McLean et al.
patent: 6110918 (2000-08-01), Busch et al.
patent: 6110932 (2000-08-01), Carpino et al.
patent: 6132774 (2000-10-01), Ke et al.
patent: 6245765 (2001-06-01), Busch et al.
patent: 6323232 (2001-11-01), Ke et al.
patent: 2128376 (1994-07-01), None
patent: 0 381 296 (1990-02-01), None
patent: 0514720 (1992-05-01), None
patent: 0509317 (1993-10-01), None
patent: 0605193 (1993-12-01), None
patent: 0 635 270 (1995-01-01), None
patent: 0635270 (1995-01-01), None
patent: 0904774 (1998-09-01), None
patent: 246921.94 (1994-02-01), None
patent: WO 95/11029 (1995-04-01), None
patent: WO 95/14666 (1995-06-01), None
patent: WO 9621656 (1996-07-01), None
patent: WO 9724369 (1997-07-01), None
patent: WO 9731640 (1997-09-01), None
patent: WO 97/46252 (1997-12-01), None
ASBMR 18th Annual Meeting, XP: 000652812, (1996).
Cheng et al., Bone, vol. 17, No. 4 (suppl.) pp. 329s-334s 1995.
Kudo et al., Journal of Endocrinology, vol. 150, pp. 223-229, 1996.
Fournier et al., Journal of Endocrinilogy, vol. 150, pp. 275-285, 1996.
Ke et al., Bone and Mineral, vol. 19, pp. 45-62, 1992.
Adachi, Journal of Rheumatology, vol. 23 Supp 45, pp. 11-14, (1996).
Kimmel et al., Osteoporosis, vol. 20, No. 3, pp. 735-758, 1994.
E. Seeman, et al., Bone, vol. 17, No. 2 Suppl. pp. 23s-29s, (1996).
D. Thompson et al., Journal of Bone and Mineral Research, vol. 11, p. S95, Aug., 1996.
Pienta, et al., The Prostate, 23, pp. 61-67, 1993.
Neubauer et al., The Prostate, 23, pp. 245-262, 1993.
Martindale, The Estra Pharmacopia, The Parm. Press, London, pp. 477 and 500, 1993.
Cheng et al.,Journal of Shanghai Medical, “Combined use of tamoxifen and DL-15-methyl prostaglandin F2 for termination of early pregnacy”, vol. 17, pp. 378-381 (1990) XP008065947 (Abstract in English only).
Williams et al, American Society of Consultant Pharmacists, pp. 1-26, “New Drugs for 1996”.
Bachmann, G.A. Nonhormonal Alternatives for the Management of Early Menopause in Younger Women with Breast Cancer; Journal of the Nat. Cancer Inst., Monographs, (1994) (16) pp. 161-167.
Wronski et al., Endocrinology, V. 132(2), pp. 823-831, (1993).
Patchett et al, Proc. Natl. Academy of Science, USA, vol. 92, pp. 7001-7005, (Jul. 1995).
Lax et al, Endocrinology, V.113(5), p. 1043-1055, (1983).
Evans et al., Endocrinology, V.134(5), pp. 2282-2288, May 1994, Abstract Only.
Lax et al., Antagonistic Action of Eatrogens, Flutamide, and Human Growth Human Growth Hormone on Androgen-Induced Changes in the Activities of Some Enzymes of Hepatic Steroid Metabolism In the Rat. Endocrinology 113(3):1043-1055 (1983).
Wronski et al., Parathyroid Hormone is More Effective tha Estrogen or Bisphosphonates for Restoration of Lost Bone Mass in Ovarieotomized Rats. Endocrinology 132(2):823-831 (1993).
Evans et al., The Effects of Raloxifene on Tibia Histomorphometry in Ovariectomized Rats. Endrocrinology 134(5):2283-2288 (1994).
Budavari et al., eds. The Merck Index, 12th Edition, entry for #8864 Somatotropin. Whitehouse Station, NJ: Merck Research Laboratories, 1996, pp. 1488-1489.
Ke, et al.,Endocrinology, “Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats” vol. 136. pp. 2435-2441, (1995).
Meng, et al.,Journal of Bone and Mineral Research, “Temporal Expression of the Anabolic Action of PTH in Cancellous Bone of Ovariectomized Rats”, vol. 11, pp. 421-429, (1996).
Neubauer et al.,Prostat, Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat,.vol. 23(3), pp. 245-62, (1993).
The Merck Index, 11thEdition, pp. 1113, 1114, 1251, (1989).
The Merck Index, 12thEdition, pp. 582, 1394, 1548, (1996).
Bachmann, Gloria A,Journal of National Cancer Institute Monographs, Nongormonal Alternatives for the Management of Early Menopause in Younger Women with Breast Cancer, vol. 16, pp. 161-167, (1994).

Affiliated with

Also associated with

Rating

Combination therapy for osteoporosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy for osteoporosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for osteoporosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3868909